These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17023755)

  • 21. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column.
    Sawada K; Muto T; Shimoyama T; Satomi M; Sawada T; Nagawa H; Hiwatashi N; Asakura H; Hibi T
    Curr Pharm Des; 2003; 9(4):307-21. PubMed ID: 12570823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroid-free elderly patients.
    Komoto S; Matsuoka K; Kobayashi T; Yokoyama Y; Suzuki Y; Hibi T; Miura S; Hokari R
    J Gastroenterol Hepatol; 2018 Aug; 33(8):1485-1491. PubMed ID: 29406567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Leukocytapheresis for ulcerative colitis].
    Sawada K; Ohnishi K; Kosaka T; Egashira A; Yamamura M; Satomi M; Shimoyama T
    Nihon Geka Gakkai Zasshi; 1997 Apr; 98(4):438-42. PubMed ID: 9168498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients.
    Fukunaga K; Fukuda Y; Yokoyama Y; Ohnishi K; Kusaka T; Kosaka T; Hida N; Ohda Y; Miwa H; Matsumoto T
    J Gastroenterol; 2006 Jun; 41(6):524-32. PubMed ID: 16868799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis.
    Shimada M; Iwase H; Tsuzuki T; Hirashima N; Kobayashi K; Hibino Y; Watanabe H; Ryuge N; Ando T; Goto H; Yagi Y; Tsujikawa T; Andoh A
    Ther Apher Dial; 2008 Oct; 12(5):368-73. PubMed ID: 18937719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Caudal type homeobox 2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis.
    Tsuchiya K; Hayashi R; Fukushima K; Hibiya S; Horita N; Negi M; Itoh E; Akashi T; Eishi Y; Motoya S; Takeuchi Y; Kunisaki R; Fukunaga K; Nakamura S; Yoshimura N; Takazoe M; Iizuka B; Suzuki Y; Nagahori M; Watanabe M
    J Gastroenterol Hepatol; 2017 May; 32(5):1032-1039. PubMed ID: 27862316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis.
    Andoh A; Ogawa A; Kitamura K; Inatomi O; Fujino S; Tsujikawa T; Sasaki M; Mitsuyama K; Fujiyama Y
    J Gastroenterol; 2004 Dec; 39(12):1150-7. PubMed ID: 15622478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis.
    Ashida T; Kohgo Y; Munakata A; Noguchi M; Iizuka B; Endo Y; Hanai H; Yoshikawa T; Matsumoto T; Aoyama N; Matsui T; Mitsuyama K; Hibi T
    Transfus Apher Sci; 2011 Apr; 44(2):113-7. PubMed ID: 21402309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study.
    Matsumoto T; Andoh A; Okawa K; Ito H; Torii A; Yoshikawa S; Nakaoka R; Okuyama Y; Oshitani N; Nishishita M; Watanabe K; Fukunaga K; Ohnishi K; Kusaka T; Yokoyama Y; Sasaki M; Tsujikawa T; Aoki T; Kusaka T; Takeda Y; Umehara Y; Nakamura S; Fujiyama Y
    Ther Apher Dial; 2008 Dec; 12(6):484-90. PubMed ID: 19140847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leukocytapheresis treatment for pyoderma gangrenosum.
    Fujimoto E; Fujimoto N; Kuroda K; Tajima S
    Br J Dermatol; 2004 Nov; 151(5):1090-2. PubMed ID: 15541092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice.
    Yokoyama Y; Matsuoka K; Kobayashi T; Sawada K; Fujiyoshi T; Ando T; Ohnishi Y; Ishida T; Oka M; Yamada M; Nakamura T; Ino T; Numata T; Aoki H; Sakou J; Kusada M; Maekawa T; Hibi T
    J Crohns Colitis; 2014 Sep; 8(9):981-91. PubMed ID: 24556083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis.
    Yagi Y; Andoh A; Inatomi O; Bamba S; Tsujikawa T; Fujiyama Y; Mitsuyama K; Yoshida T
    J Gastroenterol; 2006 Jun; 41(6):540-6. PubMed ID: 16868801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracorporeal leukocyte removal therapy for patients with ulcerative colitis.
    Kumagai M; Yamato Y; Maeda K; Nakashima E; Ushijima K; Kimura A
    Pediatr Int; 2007 Aug; 49(4):431-6. PubMed ID: 17587263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study.
    Sakata Y; Iwakiri R; Amemori S; Yamaguchi K; Fujise T; Otani H; Shimoda R; Tsunada S; Sakata H; Ikeda Y; Ando T; Nakafusa Y; Fujimoto K
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):629-33. PubMed ID: 18679064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility of five days of consecutive leukocytapheresis for the treatment of ulcerative colitis: a preliminary study.
    Tsujikawa T; Andoh A; Ogaẃa A; Sonoda A; Yagi Y; Hata K; Sasaki M; Saito Y; Fujiyama Y
    Ther Apher Dial; 2009 Feb; 13(1):14-8. PubMed ID: 19379165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis.
    Sawada K; Ohnishi K; Kosaka T; Chikano S; Yokota Y; Egashira A; Izawa H; Yamamura M; Amano K; Satomi M; Shimoyama T
    Ther Apher; 1997 Aug; 1(3):207-11. PubMed ID: 10225739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.
    Sawada K; Ohdo M; Ino T; Nakamura T; Numata T; Shibata H; Sakou J; Kusada M; Hibi T
    Ther Apher Dial; 2016 Apr; 20(2):197-204. PubMed ID: 26771066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis.
    Fukunaga K; Kamikozuru K; Yokoyama Y; Hida N; Ohda Y; Takeda N; Yoshida K; Iimuro M; Kikuyama R; Kato K; Nagase K; Nakamura S; Miwa H; Matsumoto T
    J Clin Apher; 2011 Dec; 26(6):326-31. PubMed ID: 22083887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis.
    Kanke K; Hoshino M; Tominaga K; Nakano M; Terano A; Hiraishi H
    Blood Purif; 2007; 25(4):370-6. PubMed ID: 17785966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukocytapheresis therapy modulates circulating t cell subsets in patients with ulcerative colitis.
    Andoh A; Tsujikawa T; Inatomi O; Deguchi Y; Sasaki M; Obata H; Mitsuyama K; Fujiyama Y
    Ther Apher Dial; 2005 Jun; 9(3):270-6. PubMed ID: 15967005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.